US FDA Grants Lion TCR Two Orphan Drug Designations of T cell Therapy Against Hepatocellular Carcinoma
US FDA has granted two orphan drug designations (ODD) for T cell therapy products to Singapore-based biotech company, Lion TCR Pte Ltd, for the treatment of hepatocellular carcinoma(HCC). Lion TCR are developing two product candidates — HBV specific TCR redirected T … Continued